A Phase 3 interventional study of Fluconazole in Vulvovaginal Candidiasis, sponsored by Pfizer. Completed at 10 sites in Japan. Open to female participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2021-07-19.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
As for the indication of vulvovaginal candidiasis, a single oral administration of fluconazole 150 mg has been approved and is recommended by guidelines overseas. However in Japan oral therapy with antifungal triazole such as Fluconazole has not been approved, and topical therapies such as vaginal tablets, pessary and cream are used clinically. The purpose of this trial is to confirm the efficacy and safety of single oral administration of fluconazole 150 mg for the treatment of vulvovaginal candidiasis in Japanese patients.
109 studies on the registry are indexed under Candidiasis, Vulvovaginal; 14 are open to participants now.
This study's enrollment of 157 is above the median of 126 across 91 interventional studies indexed under Candidiasis, Vulvovaginal.
Browse Candidiasis, Vulvovaginal studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Fluconazole
Single oral dose of 150mg Fluconazole
Therapeutic Outcome: Response Rate
Therapeutic outcome was determined by combination of clinical efficacy and mycological efficacy for each participant as Effective, Ineffective or Indeterminate. The therapeutic outcome was considered as Effective when the clinical efficacy was Cure and the mycological efficacy was Eradication. Primary evaluation of therapeutic outcome was on Day 28. Response rate was calculated based on the following formula, "the number of participants assessed as effective" over "total participants excluding ones assessed as indeterminate" multiplied by 100.
Time frame: Day 7, Day 14 and Day 28
Clinical Efficacy: Cure Rate
Scores of severity in signs and symptoms at each observation dates were compared with those before the treatment and the clinical efficacy was determined as Cure (the clinical symptom disappeared), Improvement (the clinical symptom was improved: the total score of clinical symptom was reduced relative to the total score before the treatment), Failure (the criteria for Cure and Improvement were not met, or other systemic antifungal drugs or local antifungal drugs were administered for the treatment of the disease to be examined) or Indeterminate (efficacy for each item was not determined for the reasons including failure to conduct the test, or other systemic antifungal agents or local antifungal drugs were administered for the treatment of infections other than the disease to be examined). Cure rate was calculated based on the following formula, "the number of participants assessed as Cure" over "total participants excluding ones assessed as Indeterminate" multiplied by 100.
Time frame: Day 7, Day 14 and Day 28
Clinical Efficacy: Cure and Improvement Rate
Scores of severity in signs and symptoms on each observation dates are compared with those before the treatment and the clinical efficacy is determined as Cure (the clinical symptom disappeared), Improvement (the clinical symptom was improved), Failure (the criteria for Cure and Improvement were not met, or other systemic antifungal drugs or local antifungal drugs were administered for the treatment of the disease to be examined) or Indeterminate (efficacy for each item was not determined for the reasons including failure to conduct the test, or other systemic antifungal agents or local antifungal drugs were administered for the treatment of infections other than the disease to be examined). Cure and improvement rate was calculated based on the following formula, "the number of participants assessed as Cure or Improvement" over "total participants excluding ones assessed as Indeterminate" multiplied by 100.
Time frame: Day 7, Day 14 and Day 28
Mycological Efficacy: Eradication Rate
Determined based on the results of culture of Candida as Eradication, Persistent or Indeterminate. Eradication rate was calculated based on the following formula, "the number of participants assessed as Eradication" over "total participants excluding ones assessed as Indeterminate" multiplied by 100.
Time frame: Day 7, Day 14 and Day 28
Total Scores for Clinical Symptoms
Sum of severity scores in vulvovaginal itching, vulvovaginal burning sensation, excoriation of vulva, vaginal discharge, vulva oedema, redness of vulva, vaginal redness, property of vaginal content. Higher scores show greater severity. Total Scores for Clinical Symptoms Severity range from 0 (best possible outcome) to 24 (worst possible outcome).
Time frame: Day 1 (before dosing), Day 3, Day 7, Day 14 and Day 28
Maximum Observed Plasma Concentration (Cmax)
Time frame: Before dosing and 2, 24, 48 and 168 hours after dosing
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Time frame: Before dosing and 2, 24, 48 and 168 hours after dosing
Area Under the Plasma Curve From Time Zero to Last Quantifiable Concentration (AUClast)
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
Time frame: Before dosing and 2, 24, 48 and 168 hours after dosing
Maximum Observed Concentration (Cmax) for Vaginal Fluid Fluconazole Concentration Adjusted by Sample Weight
Time frame: Before dosing and 2, 24, 48 and 168 hours after dosing
Time to Reach Maximum Observed Concentration (Tmax) for Vaginal Fluid Fluconazole Concentration Adjusted by Sample Weight
Time frame: Before dosing and 2, 24, 48 and 168 hours after dosing
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Vaginal Fluid Fluconazole Concentration Adjusted by Sample Weight
Area under the concentration time-curve from zero to the last measured concentration (AUClast) for Vaginal Fluid Fluconazole Concentration adjusted by Sample Weight
Time frame: Before dosing and 2, 24, 48 and 168 hours after dosing
Maximum Observed Concentration (Cmax) for Vaginal Fluid Fluconazole Concentration Adjusted by Potassium in Vaginal Fluid
Time frame: Before dosing and 2, 24, 48 and 168 hours after dosing
Time to Reach Maximum Observed Concentration (Tmax) for Vaginal Fluid Fluconazole Concentration Adjusted by Potassium in Vaginal Fluid
Time frame: Before dosing and 2, 24, 48 and 168 hours after dosing
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Vaginal Fluid Fluconazole Concentration Adjusted by Potassium in Vaginal Fluid
Area under the concentration time-curve from zero to the last measured concentration (AUClast) for Vaginal Fluid Fluconazole Concentration Adjusted by Potassium in Vaginal Fluid
Time frame: Before dosing and 2, 24, 48 and 168 hours after dosing
| Milestone | Fluconazole |
|---|---|
| Started | 157 |
| Completed | 99 |
| Not completed | 58 |
| Withdrew: Withdrawal by subject | 1 |
| Withdrew: Adverse event | 1 |
| Withdrew: Did not meet the inclusion criteria | 56 |
Therapeutic outcome was determined by combination of clinical efficacy and mycological efficacy for each participant as Effective, Ineffective or Indeterminate. The therapeutic outcome was considered as Effective when the clinical efficacy was Cure and the mycological efficacy was Eradication. Primary evaluation of therapeutic outcome was on Day 28. Response rate was calculated based on the following formula, "the number of participants assessed as effective" over "total participants excluding ones assessed as indeterminate" multiplied by 100.
| percentage of participants | Fluconazole |
|---|---|
| Day 7 (n=95) | 33.7 (24.2 to 44.3) |
| Day 14 (n=100) | 54.2 (43.7 to 64.4) |
| Day 28 (n=102) | 74.7 (65.0 to 82.9) |
Scores of severity in signs and symptoms at each observation dates were compared with those before the treatment and the clinical efficacy was determined as Cure (the clinical symptom disappeared), Improvement (the clinical symptom was improved: the total score of clinical symptom was reduced relative to the total score before the treatment), Failure (the criteria for Cure and Improvement were not met, or other systemic antifungal drugs or local antifungal drugs were administered for the treatment of the disease to be examined) or Indeterminate (efficacy for each item was not determined for the reasons including failure to conduct the test, or other systemic antifungal agents or local antifungal drugs were administered for the treatment of infections other than the disease to be examined). Cure rate was calculated based on the following formula, "the number of participants assessed as Cure" over "total participants excluding ones assessed as Indeterminate" multiplied by 100.
| percentage of participants | Fluconazole |
|---|---|
| Day 7 (n=99) | 34.8 (25.1 to 45.4) |
| Day 14 (n=101) | 57.3 (46.8 to 67.3) |
| Day 28 (n=102) | 81.6 (72.5 to 88.7) |
Scores of severity in signs and symptoms on each observation dates are compared with those before the treatment and the clinical efficacy is determined as Cure (the clinical symptom disappeared), Improvement (the clinical symptom was improved), Failure (the criteria for Cure and Improvement were not met, or other systemic antifungal drugs or local antifungal drugs were administered for the treatment of the disease to be examined) or Indeterminate (efficacy for each item was not determined for the reasons including failure to conduct the test, or other systemic antifungal agents or local antifungal drugs were administered for the treatment of infections other than the disease to be examined). Cure and improvement rate was calculated based on the following formula, "the number of participants assessed as Cure or Improvement" over "total participants excluding ones assessed as Indeterminate" multiplied by 100.
| percentage of participants | Fluconazole |
|---|---|
| Day 7 (n=99) | 100.0 (96.1 to 100.0) |
| Day 14 (n=101) | 99.0 (94.3 to 100.0) |
| Day 28 (n=102) | 95.9 (89.9 to 98.9) |
Determined based on the results of culture of Candida as Eradication, Persistent or Indeterminate. Eradication rate was calculated based on the following formula, "the number of participants assessed as Eradication" over "total participants excluding ones assessed as Indeterminate" multiplied by 100.
| percentage of participants | Fluconazole |
|---|---|
| Day 7 (n=95) | 95.7 (89.5 to 98.8) |
| Day 14 (n=100) | 89.8 (82.0 to 95.0) |
| Day 28 (n=102) | 85.9 (77.4 to 92.0) |
Sum of severity scores in vulvovaginal itching, vulvovaginal burning sensation, excoriation of vulva, vaginal discharge, vulva oedema, redness of vulva, vaginal redness, property of vaginal content. Higher scores show greater severity. Total Scores for Clinical Symptoms Severity range from 0 (best possible outcome) to 24 (worst possible outcome).
| score on s scale | Fluconazole |
|---|---|
| Day 1 (before dosing, n=102) | 11.0 (4 to 19) |
| Day 3 (n=98) | 4.5 (0 to 12) |
| Day 7 (n=93) | 1.8 (0 to 10) |
| Day 14 (n=98) | 0.8 (0 to 7) |
| Day 28 (n=99) | 0.4 (0 to 9) |
| mcg/mL | Fluconazole |
|---|---|
| Maximum Observed Plasma Concentration (Cmax) | 3.71 ± 24 |
| hours | Fluconazole |
|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) | 1.9 (1.8 to 70.3) |
Area under the plasma concentration time-curve from zero to the last measured concentration (AUClast)
| mcg*h/mL | Fluconazole |
|---|---|
| Area Under the Plasma Curve From Time Zero to Last Quantifiable Concentration (AUClast) | 156.1 ± 22 |
| mcg/g | Fluconazole |
|---|---|
| Maximum Observed Concentration (Cmax) for Vaginal Fluid Fluconazole Concentration Adjusted by Sample Weight | 1.33 ± 49 |
| hours | Fluconazole |
|---|---|
| Time to Reach Maximum Observed Concentration (Tmax) for Vaginal Fluid Fluconazole Concentration Adjusted by Sample Weight | 20.5 (1.8 to 116.6) |
Area under the concentration time-curve from zero to the last measured concentration (AUClast) for Vaginal Fluid Fluconazole Concentration adjusted by Sample Weight
| mcg*h/g | Fluconazole |
|---|---|
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Vaginal Fluid Fluconazole Concentration Adjusted by Sample Weight | 79.5 ± 43 |
| mcg/mL | Fluconazole |
|---|---|
| Maximum Observed Concentration (Cmax) for Vaginal Fluid Fluconazole Concentration Adjusted by Potassium in Vaginal Fluid | 1.53 ± 59 |
| hrs | Fluconazole |
|---|---|
| Time to Reach Maximum Observed Concentration (Tmax) for Vaginal Fluid Fluconazole Concentration Adjusted by Potassium in Vaginal Fluid | 20.5 (1.8 to 116.6) |
Area under the concentration time-curve from zero to the last measured concentration (AUClast) for Vaginal Fluid Fluconazole Concentration Adjusted by Potassium in Vaginal Fluid
| mcg*h/mL | Fluconazole |
|---|---|
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) for Vaginal Fluid Fluconazole Concentration Adjusted by Potassium in Vaginal Fluid | 85.3 ± 48 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Fluconazole | — | 0/157 (0%) | 37/157 (23.6%) |
| Event | Fluconazole |
|---|---|
| NasopharyngitisInfections and infestations | 8/157 |
| CystitisInfections and infestations | 4/157 |
| Genital herpesInfections and infestations | 4/157 |
| EczemaSkin and subcutaneous tissue disorders | 4/157 |
| DiarrhoeaGastrointestinal disorders | 3/157 |
| NauseaGastrointestinal disorders | 3/157 |
| Genital haemorrhageReproductive system and breast disorders | 3/157 |
| PyrexiaGeneral disorders | 2/157 |
| BronchitisInfections and infestations | 2/157 |
| PalpitationsCardiac disorders | 1/157 |
| Age, Continuous(years) | Fluconazole |
|---|---|
| Mean | 31.8 ± 8.5 |
| Sex: Female, Male(Participants) | Fluconazole |
|---|---|
| Female | 157 |
| Male | 0 |
Ran from Mar 2013 to primary completion in Nov 2013, 8 months.
Results were first posted in Dec 2014, 1 year after primary completion.
Of 15 phase 3 interventional studies under Candidiasis, Vulvovaginal, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's 8 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluconazole